Amarin Corporation PLC
AMRN14.920USD
+0.320+2.19%
Cierre 09/18, 16:00（ET）Cotizaciones retrasadas 15 min
309.89MCap. mercado
PérdidaP/E TTM
Más Datos de Amarin Corporation PLC Compañía
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Información de la empresa
Símbolo de cotizaciónAMRN
Nombre de la empresaAmarin Corporation PLC
Fecha de salida a bolsaApr 01, 1993
Director ejecutivoMr. Aaron D. Berg
Número de empleados275
Tipo de seguridadDepository Receipt
Fin del año fiscalApr 01
DirecciónWeWork One Central Plaza Dame Street
CiudadDUBLIN
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísIreland
Código postalD02 K7K5
Teléfono35316699020
Sitio Webhttps://amarincorp.com/
Símbolo de cotizaciónAMRN
Fecha de salida a bolsaApr 01, 1993
Director ejecutivoMr. Aaron D. Berg
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Mr. Oliver O'Connor
Mr. Oliver O'Connor
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Dr. Paul Cohen, M.D.
Dr. Paul Cohen, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Ms. Patrice Bonfiglio
Ms. Patrice Bonfiglio
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Louis Sterling, III
Mr. Louis Sterling, III
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Peter Fishman
Mr. Peter Fishman
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Stephen B. (Steven) Ketchum, Ph.D.
Dr. Stephen B. (Steven) Ketchum, Ph.D.
President - Research and Development, Executive Vice President, Chief Scientific Officer
President - Research and Development, Executive Vice President, Chief Scientific Officer
--
--
Mr. Aaron D. Berg
Mr. Aaron D. Berg
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Keith L. Horn
Mr. Keith L. Horn
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Odysseas D. Kostas, M.D.
Dr. Odysseas D. Kostas, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Mr. Oliver O'Connor
Mr. Oliver O'Connor
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Dr. Paul Cohen, M.D.
Dr. Paul Cohen, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Ms. Patrice Bonfiglio
Ms. Patrice Bonfiglio
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Louis Sterling, III
Mr. Louis Sterling, III
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Peter Fishman
Mr. Peter Fishman
Chief Financial Officer
Chief Financial Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 9 de sep
Actualizado: mar., 9 de sep
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Sarissa Capital Management, L.P.
6.01%
Kynam Capital Management LP
2.79%
Acadian Asset Management LLC
1.17%
Eversept Partners, LP
0.81%
Morgan Stanley & Co. LLC
0.71%
Otro
88.52%
Accionistas
Accionistas
Proporción
Sarissa Capital Management, L.P.
6.01%
Kynam Capital Management LP
2.79%
Acadian Asset Management LLC
1.17%
Eversept Partners, LP
0.81%
Morgan Stanley & Co. LLC
0.71%
Otro
88.52%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
11.46%
Investment Advisor
3.11%
Investment Advisor/Hedge Fund
1.77%
Research Firm
1.32%
Individual Investor
0.95%
Foundation
0.18%
Family Office
0.10%
Pension Fund
0.09%
Otro
81.01%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
337
3.85M
18.61%
-1.56M
2025Q1
349
5.67M
20.22%
+144.25K
2024Q4
362
81.89M
19.91%
-21.31M
2024Q3
365
76.69M
18.66%
-50.88M
2024Q2
389
87.45M
21.29%
-59.57M
2024Q1
405
98.68M
24.03%
-57.40M
2023Q4
423
103.82M
25.42%
-56.37M
2023Q3
447
95.61M
23.44%
-78.96M
2023Q2
464
107.90M
26.46%
-89.05M
2023Q1
492
118.85M
29.19%
-104.01M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Sarissa Capital Management, L.P.
1.24M
6%
--
--
Mar 31, 2025
Kynam Capital Management LP
620.73K
3%
--
--
Mar 31, 2025
Acadian Asset Management LLC
189.58K
0.92%
+100.29K
+112.31%
Mar 31, 2025
Eversept Partners, LP
169.96K
0.82%
+94.13K
+124.13%
Mar 31, 2025
Morgan Stanley & Co. LLC
116.05K
0.56%
-87.42K
-42.96%
Mar 31, 2025
SCP Investment, LP
125.00K
0.6%
--
--
Mar 31, 2025
WaterFront Wealth, Inc.
125.73K
0.61%
+1.64K
+1.32%
Mar 31, 2025
Longitude (Cayman) Ltd
81.00K
0.39%
-37.50K
-31.65%
Dec 31, 2024
Berg (Aaron D.)
80.71K
0.39%
+36.64K
+83.12%
Jun 26, 2025
Two Sigma Investments, LP
162.85K
0.79%
-33.32K
-16.99%
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Mar 12, 2025
Merger
20→1
Fecha
Tipo
Relación
Mar 12, 2025
Merger
20→1
